• Published at the 21st International Myeloma Society Annual Meeting – 2024

  • Collaborator: Johnson & Johnson

  • Authors: Beth Faiman, Hoa Le, Julie Laurent, Saurabh Patel, Agne Paner‑Straseviciute, Xinke
    Zhang, Joseph Mikhael

The treatment landscape for patients with relapsed refractory multiple myeloma (RRMM) has witnessed remarkable advancements with the introduction of novel therapies as later line options in recent years. Gaining a deeper understanding of how various factors influence patients’
treatment preferences is crucial. This study is designed to assess patient preferences between treatment characteristics that are consistent with the therapeutic options available to these patients.